Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

807 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-02-28

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pediacel™ is currently licensed in the UK for use as a 3 dose regimen for the active immunisation of infants against Diphtheria, Tetanus, Pertussis, Poliomyelitis and invasive infections caused by Haemophilus influenzae type b. However there are currently no clinical data supporting the use of Pediacel™ using a 3, 5, and 12 months of age vaccination schedule. This study is designed to provide safety and immunogenicity data to support the use of Pediacel™ according to a 3, 5, and 12 months schedule.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

NCT00343421

Diphtheria Tetanus Pertussis +2 more

COMPLETED PHASE3

Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®

NCT00355654

Infant Healthy

COMPLETED PHASE3

Interchangeability of Infanrix™ IPV/Hib and Pediacel® at 2,4 & 6 Months of Age

NCT00990080

Infant Immunizations

COMPLETED PHASE3

Safety and Immune Response of Different Pediatric Combination Vaccines.

NCT00255047

Diphtheria Polio Pertussis

COMPLETED PHASE3

Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants

NCT00879827

Diphtheria Poliomyelitis Hepatitis B +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pertussis Diphtheria Tetanus Poliomyelitis Haemophilus Influenzae Type b

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Participants will receive PEDIACEL vaccine

Group Type EXPERIMENTAL

DT5aP-IPV-Hib 5-component Pertussis vaccine

Intervention Type BIOLOGICAL

0.5 mL, IM

Group 2

Participants will receive Infanrix-IPV+Hib vaccines

Group Type ACTIVE_COMPARATOR

Infanrix® -IPV+Hib

Intervention Type BIOLOGICAL

0.5 mL, IM

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DT5aP-IPV-Hib 5-component Pertussis vaccine

0.5 mL, IM

Intervention Type BIOLOGICAL

Infanrix® -IPV+Hib

0.5 mL, IM

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pediacel™ Infanrix®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants aged 80 to 120 days inclusive on the day of inclusion.
* Born at full term of pregnancy (\> 37 weeks)
* Informed consent form signed by the parent(s) or other legal representative according to local regulations
* Parent(s) or legal representative able to attend all scheduled visits and to understand and comply with the study procedures (able to read and write; access to a telephone).

Exclusion Criteria

* Rectal temperature ≥ 38.0°C
* Moderate or severe acute illness with or without fever
* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination
* Having received any DTaP, IPV, or Hib vaccines prior to study initiation or any vaccination in the 4 weeks preceding the first trial vaccination
* Planned participation in another clinical trial during the present trial period
* Known history of diphtheria, tetanus, pertussis, H. influenzae type b infections, poliomyelitis
* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy
* Systemic hypersensitivity to any of the vaccine components (including neomycin, streptomycin, polymyxin B and formaldehyde)
* History of a life-threatening reaction (such as encephalopathy, Hypotonic Hyporesponsive Episode, severe fever, convulsions, etc.) to the trial vaccine or a vaccine containing the same substances
* Blood or blood-derived products (immunoglobulins) received in the past 4 weeks
* Vaccination planned in the 6 weeks following any trial vaccination
* Known HIV seropositivity
* Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination
* History of seizures or progressive, evolving or unstable neurological condition
* Clinically significant findings on review of systems that might interfere with correct vaccination or which, in the opinion of the Investigator, would interfere with the evaluation of the vaccine or pose a health risk to the subject.

Minimum Eligible Age

80 Days

Maximum Eligible Age

120 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes